Concepedia

Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4′-hydroxylation phenotype and genotype*

Μakoto Tanaka, Tadashi Ohkubo, Koichi Otani, Akihito Suzuki, Sunao Kaneko, Kazunobu Sugawara, Yuichi Ryokawa, Hideo Hakusui, Shunji Yamamori, Takashi Ishizaki

Clinical Pharmacology & Therapeutics · 1997 · 73 citations · 37 references

DOI

Abstract

These data indicated that the metabolic disposition of pantoprazole is under the pharmacogenetic control of S-mephenytoin 4'-hydroxylase (CYP2C19).

References

37

The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.

S.M. de Morais, G. Wilkinson, Joyce Blaisdell et al. · Journal of Biological Chemistry · 1994 · 952 citations · Full text

Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.

Sara Moráis, G. Wilkinson, Joyce Blaisdell et al. · Molecular Pharmacology · 1994 · 750 citations

Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations

Kōichi Nakamura, Fumio Goto, Wayne A. Ray et al. · Clinical Pharmacology & Therapeutics · 1985 · 456 citations

Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man

A. K�pfer, R Preisig · European Journal of Clinical Pharmacology · 1984 · 363 citations

, ,

Evidence That CYP2C19 is the Major (S)-Mephenytoin 4'-Hydroxylase in Humans

Jorge Goldstein, M B Faletto, M Romkes-Sparks et al. · Biochemistry · 1994 · 363 citations